Hsin-Hui Huang

AbbVie (United States) — United States

Medicine · Health Sciences

22h-index4.5kcitations196works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(48), Cancer Immunotherapy and Biomarkers(44), HER2/EGFR in Cancer Research(27), Colorectal Cancer Treatments and Studies(27), Lung Cancer Treatments and Mutations(24)

Publications196 total

Comparative efficacy of ibrutinib versus other covalent Bruton tyrosine kinase inhibitors (cBTKis) in first-line (1L) chronic lymphocytic leukemia (CLL): A matched-adjusted indirect comparison (MAIC).
Journal of Clinical Oncology·2025
Autonomous Navigation for Human-Following Robots Based on Optimized Position Tracking
2025
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2025Open Access
Applying AI Mind Mapping to Empower Patients with Schizophrenia
Preprints.org·2025Open Access
Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
Blood·2024· 2 citedOpen Access
Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
Blood·2024· 1 citedOpen Access
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Yi-Tsung Lin(9), Tsuey‐Ching Yang(9), Yi-Wei Huang(5), Jashvant Poeran(5), Richard K. Zimmerman(5), Mary Patricia Nowalk(5), Chyongchiou J. Lin(5), Madhu Mazumdar(4), Alaina J. Kessler(4), Jimmy J. Chan(4), Li-Hua Li(4), Sacha Gnjatic(3), Yongqun He(3), Hong Yu(3), Edison Ong(3), Yingtong Liu(3), Anthony Huffman(3), John Beverley(3), Junguk Hur(3), Luonan Chen(3)